Navigation Links
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
Date:3/15/2010

inical trials; reliance on third parties to manufacture, market and distribute many of our products; our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT - G

SOURCE Savient Pharmaceuticals, Inc.


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
2. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
3. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
4. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
7. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Savient Provides Update on Pegloticase BLA
9. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... or "the Company"), a clinical stage biopharmaceutical company ... targeted therapeutics for the treatment of inflammatory diseases ... previously announced underwritten public offering of 3,450,000 units, ... the Company,s common stock, par value $0.0001 per ...
(Date:11/24/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... update at the Piper Jaffray 26 th Annual Healthcare ... Time (5:30 a.m. Pacific Time), at The New York Palace ... A live audio webcast of the presentation will be available ... www.arenapharm.com . A replay of the presentation will be available ...
(Date:11/24/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... today that Sergio Traversa , chief executive officer, ... Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014.  ... Bel Air Hotel, which is located at 11461 Sunset ... The presentation is scheduled for 8:30 a.m. ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Relmada Therapeutics To Present At LD MICRO Conference 2
... , MISSISSAUGA, Ontario, Dec. 30 ... Holdings Inc. (OTC Bulletin Board: CGNH), a developer of ... IVD testing market, was interviewed in MedTech Executive. ... for developing its QL Care Analyzer device, the FDA ...
... , BOSTON, Dec. 30 Solos Endoscopy, ... looks forward to a prosperous 2010, following a solid year in ... , In the closing months of 2009, Solos Endoscopy, Inc. has ... MammoView(TM) line of surgical endoscopy instruments. This will allow the MammoView(TM) ...
Cached Medicine Technology:Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive 2Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive 3Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive 4Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010 2
(Date:11/26/2014)... the video interviewing specialist, has today announced the appointment ... Officer, in addition to the formal opening of it’s ... appointed as Chief Operating Officer. He is joined by ... Officer. , Mr Jones is a seasoned tech, media ... with The Walt Disney Company and Adventis where he ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Anthropologists ... effectiveness in containing and stopping Ebola, improve international ... in healthcare systems in West Africa. , ... to Stop Ebola: Anthropologists Offer Insights,” will be ... the American Anthropological Association (AAA), Fri., Dec. 5, ...
(Date:11/26/2014)... Medical suction and vacuum products have a ... score represents steady growth in the price of medical ... a result of swelling demand for healthcare services and ... considered nondiscretionary. IBISWorld market research analyst, Anna Son, says, ... of flexibility, given the low level of price volatility ...
(Date:11/26/2014)... For those with a New Year’s resolution to ... classes at the University of Colorado Anschutz Health and ... for. The 45- 60 minute classes have just started and ... fitness club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, ... aimed at fast results , By focusing on low ...
(Date:11/26/2014)... November 26, 2014 News Facts ... expanded capabilities at RSNA 2014 in Chicago. The ... and share diagnostic images, photos, videos and documents ... booth #8107 will learn more about these innovative ... technologies and partner initiatives – that enable more ...
Breaking Medicine News(10 mins):Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3
... to Accelerate Adoption, WASHINGTON, Dec. 5 ... improve health care through electronic prescribing (e-prescribing), ... bipartisan,legislation introduced by Senate Finance Committee Members ... (D-Mich.), Senator Mel,Martinez (R-Fla.), and endorsed by ...
... Two studies support efforts to reduce air pollution, especially ... Two real-world studies from Europe demonstrate the health damage ... by diesel engines. , An 11-year period of improving ... the cleanest air in Europe, produced measurable benefits in ...
... portfolio, SHAWNEE, Kan., Dec. 5 AVP ... industry, will change its name to Avascend,effective December ... brand is the,expanded service portfolio and the same ... Avascend currently provides the following core healthcare hospitality,services: ...
... lifestyle drives new store openings, PITTSBURGH, Dec. 5 ... resolution or two. For GNC, it means more new ... expected to rise steadily,through 2012, according to the Nutrition ... once again expand its store base and overall,business: The ...
... DND, MISSISSAUGA, ON, Dec. 5 /PRNewswire-FirstCall/ - ... Stefan Aigner, M.D., CFA, has been,appointed to its ... than 20 years of experience in the global,healthcare ... Business,Development for Alpharma, Inc. (NYSE: ALO ), ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the ... of its Board of Directors has granted ... to encourage their,long-term retention and reward performance. ... the Company,s Chief Investment Officer, Richard A.,Schweinhart, ...
Cached Medicine News:Health News:PCMA Supports Bipartisan Legislation Calling for E-Prescribing Requirement in Medicare 2Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3Health News:AVP is Now Avascend 2Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Cipher appoints Stefan Aigner to board of directors 2Health News:Cipher appoints Stefan Aigner to board of directors 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4
Micro-Kerrison Laminectomie Rongeur and Stella Punch, golden springs, with ejector. 18 cm - 7 1/8, very delicate, narrow footplate, small handle, 40 up-cutting, jaws 2 mm wide....
Kerrison (Micro) Laminectomy rongeur with ejector. 18 cm - 7 1/8, thick footplate, small handle, very delicate, 40 up-cutting, jaws 2 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
... ValveTM, Hakim, H-V Lumbar Valve ... for meeting the complex demands ... response causes the valve to ... present, eliminating the need for ...
Medicine Products: